Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistance
A. Lyczek, B.-T. Berger, A. M. Rangwala, Y. Paung, J. Tom, H. Philipose, J. Guo, S. K. Albanese, M. B. Robers, S. Knapp, J. D. Chodera, M. A. Seeliger
The paper identifies a mutation in Abl kinase that causes imatinib resistance through altered drug dissociation kinetics rather than reduced binding affinity.
bioRxiv · Jun 28, 2021Biochemistry